Effects of infection and disease with Mycobacterium tuberculosis on serum antibody to glucan and arabinomannan: two surface polysaccharides of this pathogen.

Wendy A Keitel, ZhongDong Dai, Robert W Awe, Robert L Atmar, Sheldon Morris, Rachel Schneerson, John B Robbins
Author Information
  1. Wendy A Keitel: Department of Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, USA. wkeitel@bcm.edu

Abstract

BACKGROUND: The role of the surface capsular polysaccharides (CPs) of Mycobacterium tuberculosis (Mtb) in the pathogenesis of infection and disease, as well their potential for use as diagnostic reagents and vaccine antigens, are unknown.
METHODS: Serum antibody to two CPs of Mtb, arabinomannan (AM) and glucan (Glu), were studied in samples from 52 18-74 year-old HIV-seronegative, immunocompetent individuals in Houston Texas. The effects of Mtb exposure, infection and disease upon the levels of antibodies to these CPs were assessed. Subjects were grouped according to the standard international classification.
RESULTS: IgA anti-Glu levels were significantly higher in the active and treated TB compared to a group that was PPD-negative without TB exposure history (p<0.05). Antibodies against AM demonstrated a similar pattern, with the exception that IgG anti-AM was higher in groups who had active TB or previously documented active TB, and IgA anti-AM was higher in subjects with previously documented active TB compared to the level in an unexposed, PPD-negative group (p<0.05). Serum IgG anti-Glu levels were higher in subjects with active TB or previously documented active TB than in the unexposed PPD-negative group, but the differences were not significant.
CONCLUSIONS: These data suggest that the evaluation of antibody responses to the CP of Mtb may have utility for TB serodiagnosis, and that vaccines designed to induce humoral responses to TB CPs should be tested for their capacity to evoke anti-tuberculosis protective immunity.

References

  1. JAMA. 1994 Mar 2;271(9):698-702 [PMID: 8309034]
  2. Infect Immun. 2004 Oct;72(10):5676-86 [PMID: 15385466]
  3. World Health Organ Tech Rep Ser. 1977;(610):1-133 [PMID: 411264]
  4. Vaccine. 2003 Sep 8;21(25-26):4081-93 [PMID: 12922145]
  5. Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15688-93 [PMID: 9861031]
  6. J Pediatr. 1988 May;112(5):695-702 [PMID: 3361379]
  7. Trans R Soc Trop Med Hyg. 1992 Nov-Dec;86(6):686-92 [PMID: 1287946]
  8. Commun Dis Public Health. 2002 Sep;5(3):220-5 [PMID: 12434692]
  9. J Clin Microbiol. 2004 Jul;42(7):3225-31 [PMID: 15243086]
  10. Clin Vaccine Immunol. 2012 Feb;19(2):198-208 [PMID: 22169090]
  11. Tuber Lung Dis. 1999;79(3):153-69 [PMID: 10656114]
  12. Microbiology (Reading). 1995 Jul;141 ( Pt 7):1609-20 [PMID: 7551029]
  13. Am J Respir Crit Care Med. 2000 Apr;161(4 Pt 1):1376-95 [PMID: 10764337]
  14. Clin Diagn Lab Immunol. 1995 Jul;2(4):443-7 [PMID: 7583921]
  15. Infect Immun. 2002 May;70(5):2566-75 [PMID: 11953397]
  16. Am Rev Tuberc. 1956 Apr;73(4):547-62 [PMID: 13302685]
  17. Mol Microbiol. 2008 Nov;70(3):762-74 [PMID: 18808383]
  18. Methods Enzymol. 1990;184:537-41 [PMID: 2388588]
  19. Microbiology (Reading). 1996 Jun;142 ( Pt 6):1513-1520 [PMID: 8704991]

Grants

  1. /Intramural NIH HHS

MeSH Term

Adolescent
Adult
Aged
Antibodies, Bacterial
Antigens, Bacterial
Female
Glucans
Humans
Male
Mannans
Middle Aged
Mycobacterium tuberculosis
Pilot Projects
Polysaccharides, Bacterial
Tuberculosis

Chemicals

Antibodies, Bacterial
Antigens, Bacterial
Glucans
Mannans
Polysaccharides, Bacterial
arabinomannan

Word Cloud

Created with Highcharts 10.0.0TBactiveCPsMtbhigherinfectiondiseaseantibodylevelsgroupPPD-negativepreviouslydocumentedsurfacepolysaccharidesMycobacteriumtuberculosisSerumtwoAMglucanexposureIgAanti-Glucomparedp<005IgGanti-AMsubjectsunexposedresponsesBACKGROUND:rolecapsularpathogenesiswellpotentialusediagnosticreagentsvaccineantigensunknownMETHODS:arabinomannanGlustudiedsamples5218-74year-oldHIV-seronegativeimmunocompetentindividualsHoustonTexaseffectsuponantibodiesassessedSubjectsgroupedaccordingstandardinternationalclassificationRESULTS:significantlytreatedwithouthistoryAntibodiesdemonstratedsimilarpatternexceptiongroupsleveldifferencessignificantCONCLUSIONS:datasuggestevaluationCPmayutilityserodiagnosisvaccinesdesignedinducehumoraltestedcapacityevokeanti-tuberculosisprotectiveimmunityEffectsserumarabinomannan:pathogen

Similar Articles

Cited By